Literature DB >> 1985883

Human ovarian cancer xenografts in nude mice: characterization and analysis of antigen expression.

C F Molthoff1, J J Calame, H M Pinedo, E Boven.   

Abstract

We have characterized 13 different human ovarian cancer xenografts grown subcutaneously in nude mice. The tumor lines represented 5 histological subtypes: serous (4), mucinous (4), clear-cell carcinoma (1), carcinosarcoma (1) and undifferentiated (3). The specific histology and the degree of differentiation resembled those of the original patients' tumors and were maintained upon serial transfer. Volume doubling times of the xenografts ranged from 3.5 to 15 days. The xenografts were also analyzed for their antigen expression using 20 monoclonal antibodies (MAbs) reactive with 15 tumor-associated antigens. Immunohistochemical examination of tissue sections showed a positive reaction pattern with MAbs 115D8, 140C1, 139H2, 175C5, HMFG1 and HMFG2, each recognizing episialin, as well as with MAbs AUA1, 358.4.32 and 199-157 in xenografts of the serous, mucinous and clear-cell carcinoma subtype. MAb OC125 was reactive with xenografts of the serous subtypes. Other antibodies, such as 494 and OV-TL3 infrequently demonstrated positive reactions. Reactivity of all MAbs was low in the carcinosarcoma and undifferentiated tumor lines. With the exception of AUA1, 495 and 126E5, all MAbs revealed a heterogeneous staining pattern. MAbs against episialin and OC125 predominantly stained the apical site of the tumor cells. Strongest reactivity with almost all histological subtypes was observed with MAbs 115D8, 140C1, 139H2 and AUA1. In cases where we were able to compare the patients' tumor tissue with the respective xenografts, retention of antigen expression was demonstrated in each instance. Release of tumor-associated antigens was shown for CA125 in 2 serous-tumor lines, for CA15.3 in 1 serous-tumor line, and for CEA in 3 lines of the mucinous subtype. This panel of human tumor xenografts could be a valuable tool to determine the potential usefulness of MAb-guided therapy in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1985883     DOI: 10.1002/ijc.2910470114

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  New human ovarian cell line OVCCR1/sf in serum-free medium.

Authors:  S Jozan; H Roché; F Cheutin; M Carton; B Salles
Journal:  In Vitro Cell Dev Biol       Date:  1992 Nov-Dec

2.  Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking.

Authors:  Michael G Woo; Kai Xue; Jiayin Liu; Heidi McBride; Benjamin K Tsang
Journal:  J Biol Chem       Date:  2011-11-23       Impact factor: 5.157

3.  Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts.

Authors:  Monique C A Duyndam; Marion C G W Hilhorst; Hennie M M Schlüper; Henk M W Verheul; Paul J van Diest; Georg Kraal; Herbert M Pinedo; Epie Boven
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

4.  Pharmacokinetics and biodistribution of a new anti-episialin monoclonal antibody 139H2 in ovarian-cancer-bearing nude mice.

Authors:  C F Molthoff; H M Pinedo; H M Schlüper; E Boven
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2'-deoxy-2'-[18F]fluoro-D-glucose (FDG) and 3'-[18F]fluoro-3'-deoxythymidine (FLT).

Authors:  Carla F M Molthoff; Bianca M Klabbers; Johannes Berkhof; Jasper T Felten; Marcelle van Gelder; Albert D Windhorst; Ben J Slotman; Adriaan A Lammertsma
Journal:  Mol Imaging Biol       Date:  2007 Nov-Dec       Impact factor: 3.488

6.  Cancer immunotherapy by immunosuppression.

Authors:  Richmond T Prehn; Liisa M Prehn
Journal:  Theor Biol Med Model       Date:  2010-12-15       Impact factor: 2.432

7.  Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model.

Authors:  David Pépin; Zhong-Qi Shao; Geneviève Huppé; Andrea Wakefield; Chee-Wui Chu; Zahra Sharif; Barbara C Vanderhyden
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

Review 8.  An immune reaction may be necessary for cancer development.

Authors:  Richmond T Prehn
Journal:  Theor Biol Med Model       Date:  2006-02-03       Impact factor: 2.432

9.  Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.

Authors:  C F Molthoff; H M Pinedo; H M Schlüper; H W Nijman; E Boven
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

10.  The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.

Authors:  E Boven; H Schipper; C A Erkelens; S A Hatty; H M Pinedo
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.